RP Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-3,700
| Closed | -$74 | – | 4 |
|
|
2025
Q1 | $74 | Hold |
3,700
| – | – | ﹤0.01% | 4 |
|
|
2024
Q4 | $851 | Hold |
3,700
| – | – | ﹤0.01% | 4 |
|
|
2024
Q3 | $851 | Hold |
3,700
| – | – | ﹤0.01% | 4 |
|
|
2024
Q2 | $2K | Hold |
3,700
| – | – | ﹤0.01% | 4 |
|
|
2024
Q1 | $3.77K | Hold |
3,700
| – | – | ﹤0.01% | 3 |
|
|
2023
Q4 | $2.11K | Hold |
3,700
| – | – | ﹤0.01% | 3 |
|
|
2023
Q3 | $3.85K | Hold |
3,700
| – | – | ﹤0.01% | 3 |
|
|
2023
Q2 | $5.22K | Hold |
3,700
| – | – | 0.01% | 3 |
|
|
2023
Q1 | $5.88K | Hold |
3,700
| – | – | 0.01% | 3 |
|
|
2022
Q4 | $5.4K | Hold |
3,700
| – | – | 0.01% | 3 |
|
|
2022
Q3 | $16K | Hold |
3,700
| – | – | 0.01% | 3 |
|
|
2022
Q2 | $18K | Hold |
3,700
| – | – | 0.01% | 5 |
|
|
2022
Q1 | $18K | Hold |
3,700
| – | – | 0.01% | 5 |
|
|
2021
Q4 | $13.5M | Hold |
3,700
| – | – | 5.65% | 4 |
|
|
2021
Q3 | $30K | Hold |
3,700
| – | – | 0.01% | 4 |
|
|
2021
Q2 | $42K | Hold |
3,700
| – | – | 0.02% | 4 |
|
|
2021
Q1 | $34K | Sell |
3,700
-33,305
| -90% | -$347K | 0.01% | 5 |
|
|
2020
Q4 | $26K | Hold |
37,005
| – | – | 0.01% | 5 |
|
|
2020
Q3 | $16K | Buy |
37,005
+33,305
| +900% | +$291K | ﹤0.01% | 6 |
|
|
2020
Q2 | $34K | Hold |
3,700
| – | – | 0.01% | 6 |
|
|
2020
Q1 | $53K | Hold |
3,700
| – | – | 0.02% | 6 |
|
|
2019
Q4 | $44K | Hold |
3,700
| – | – | 0.01% | 6 |
|
|
2019
Q3 | $93K | Hold |
3,700
| – | – | 0.06% | 4 |
|
|
2019
Q2 | $95K | Hold |
3,700
| – | – | 0.06% | 4 |
|
|
2019
Q1 | $158K | Hold |
3,700
| – | – | 0.08% | 4 |
|
|
2018
Q4 | $54K | Buy |
+3,700
| New | +$151K | 0.04% | 4 |
|
RP Management's VIRX Position: Q2 2025 in Review
RP Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q2 2025, closing a stake of 3,700 shares — an estimated $74 sold.
RP Management first reported a position in VIRX in Q4 2018 and held it in 26 quarters. The position peaked at $13.5M in Q4 2021. 0 funds tracked by Wall St. Rank hold VIRX as of Q2 2025.
- RP Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q2 2025 after selling out during the quarter.
- RP Management sold 3,700 Viracta Therapeutics, Inc. Common Stock shares in Q2 2025, an estimated $74.
- RP Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2018 and held it in 26 quarters.
- RP Management's Viracta Therapeutics, Inc. Common Stock position peaked at $13.5M in Q4 2021.
- 0 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q2 2025.
Based on RP Management's 13F filing for Q2 2025.